203 related articles for article (PubMed ID: 35631331)
21. Recent Progress in 1H-1,2,3-triazoles as Potential Antifungal Agents.
Poonia N; Kumar A; Kumar V; Yadav M; Lal K
Curr Top Med Chem; 2021; 21(23):2109-2133. PubMed ID: 34517801
[TBL] [Abstract][Full Text] [Related]
22. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
Makol A; Kaur H; Sharma S; Kanthaje S; Kaur R; Chakraborti A
Clin Mol Hepatol; 2020 Jan; 26(1):45-53. PubMed ID: 31564085
[TBL] [Abstract][Full Text] [Related]
23. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
24. Targeted Delivery of Glypican 3 (GPC3) Antibody-Modified MicroRNA (miR let-7b-5p) Polymer Nanoparticles to Sorafenib-Resistant Hepatsocellular Carcinoma Cells.
Zhou S; Ma Y; Liu X; Yu P; Huang N; Song L; Xu R; Huo Z; Zhu T; Tang X
J Biomed Nanotechnol; 2021 Apr; 17(4):677-690. PubMed ID: 35057893
[TBL] [Abstract][Full Text] [Related]
25. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
Chen Y; Feng F; Gao X; Wang C; Sun H; Zhang C; Zeng Z; Lu Y; An L; Qu J; Wang F; Yang Y
Curr Cancer Drug Targets; 2015; 15(3):176-87. PubMed ID: 25714700
[TBL] [Abstract][Full Text] [Related]
26. 7-Chloroquinolinotriazoles: synthesis by the azide-alkyne cycloaddition click chemistry, antimalarial activity, cytotoxicity and SAR studies.
Pereira GR; Brandão GC; Arantes LM; de Oliveira HA; de Paula RC; do Nascimento MF; dos Santos FM; da Rocha RK; Lopes JC; de Oliveira AB
Eur J Med Chem; 2014 Feb; 73():295-309. PubMed ID: 24469080
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach.
Gao P; Sun L; Zhou J; Li X; Zhan P; Liu X
Expert Opin Drug Discov; 2016 Sep; 11(9):857-71. PubMed ID: 27400283
[TBL] [Abstract][Full Text] [Related]
28. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Abbattista MR; Jamieson SM; Gu Y; Nickel JE; Pullen SM; Patterson AV; Wilson WR; Guise CP
Cancer Biol Ther; 2015; 16(4):610-22. PubMed ID: 25869917
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and anticancer activity of dimeric podophyllotoxin derivatives.
Zi CT; Yang L; Xu FQ; Dong FW; Yang D; Li Y; Ding ZT; Zhou J; Jiang ZH; Hu JM
Drug Des Devel Ther; 2018; 12():3393-3406. PubMed ID: 30349193
[TBL] [Abstract][Full Text] [Related]
30. Semi-synthesis of β-keto-1,2,3-triazole derivatives from ethinylestradiol and evaluation of the cytotoxic activity.
Queiroz TM; Orozco EVM; Silva VR; Santos LS; Soares MBP; Bezerra DP; Porto ALM
Heliyon; 2019 Sep; 5(9):e02408. PubMed ID: 31517128
[TBL] [Abstract][Full Text] [Related]
31. Quercetin-3-O-glucoside induces human DNA topoisomerase II inhibition, cell cycle arrest and apoptosis in hepatocellular carcinoma cells.
Sudan S; Rupasinghe HP
Anticancer Res; 2014 Apr; 34(4):1691-9. PubMed ID: 24692698
[TBL] [Abstract][Full Text] [Related]
32. Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma.
Yang X; Liu J; Liang Q; Sun G
Fundam Clin Pharmacol; 2021 Aug; 35(4):690-699. PubMed ID: 33015852
[TBL] [Abstract][Full Text] [Related]
33. Heterometallic alumo- and gallodisilicates with M(O-Si-O)2M' and [M(O-Si-O)2]2M' cores (M = Al, Ga; M' = Ti, Zr, Hf).
Huerta-Lavorie R; Solis-Ibarra D; Báez-Rodríguez DV; Reyes-Lezama M; de las Nieves Zavala-Segovia M; Jancik V
Inorg Chem; 2013 Jun; 52(12):6934-43. PubMed ID: 23718324
[TBL] [Abstract][Full Text] [Related]
34. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
Rangwala F; Williams KP; Smith GR; Thomas Z; Allensworth JL; Lyerly HK; Diehl AM; Morse MA; Devi GR
BMC Cancer; 2012 Sep; 12():402. PubMed ID: 22963400
[TBL] [Abstract][Full Text] [Related]
35. A New Series of Triazolothiadiazines as Potential Anticancer Agents for Targeted Therapy of Non-Small Cell Lung and Colorectal Cancers: Design, Synthesis, In silico and In vitro Studies Providing Mechanistic Insight into Their Anticancer Potencies.
Sever B; Altıntop MD; Çiftçi GA; Özdemir A
Med Chem; 2021; 17(10):1104-1128. PubMed ID: 33087032
[TBL] [Abstract][Full Text] [Related]
36. OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53.
Omar HA; Tolba MF; Hung JH; Al-Tel TH
Front Pharmacol; 2016; 7():463. PubMed ID: 27965580
[No Abstract] [Full Text] [Related]
37. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
38. Investigation of possible effects of apigenin, sorafenib and combined applications on apoptosis and cell cycle in hepatocellular cancer cells.
Şirin N; Elmas L; Seçme M; Dodurga Y
Gene; 2020 May; 737():144428. PubMed ID: 32045658
[TBL] [Abstract][Full Text] [Related]
39. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
[TBL] [Abstract][Full Text] [Related]
40. Bee venom and its active component Melittin synergistically potentiate the anticancer effect of Sorafenib against HepG2 cells.
Mansour GH; El-Magd MA; Mahfouz DH; Abdelhamid IA; Mohamed MF; Ibrahim NS; Hady A Abdel Wahab A; Elzayat EM
Bioorg Chem; 2021 Nov; 116():105329. PubMed ID: 34544028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
